---
title: "Innovative Drug Data Presented at ADA Meeting Promises Holistic Health Improvements"
description: "Innovative Drug Data Presented at ADA Meeting Promises Holistic Health Improvements"

---


:::info

"Informed AI News" is an publications aggregation platform, ensuring you only gain the most valuable information, to eliminate information asymmetry and break through the limits of information cocoons.  [Find out more >>](/)

:::

# Innovative Drug Data Presented at ADA Meeting Promises Holistic Health Improvements

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">


Eli Lilly and other pharmaceutical companies presented encouraging data on weight loss and diabetes treatments at the American Diabetes Association's annual meeting. These companies are venturing into innovative strategies beyond conventional GLP-1 medications, focusing not only on weight loss but also on addressing other health issues and maintaining lean muscle mass.

Eli Lilly's Zepbound, a weight loss injection, demonstrated potential in alleviating obstructive sleep apnea in nearly half of the patients. Novo Nordisk's semaglutide, utilized in Wegovy and Ozempic, showed significant benefits in slowing the progression of kidney disease and reducing mortality risks in diabetes patients with chronic kidney disease. Zealand Pharma's petrelintide, which targets the amylin hormone, resulted in substantial weight loss in early trials. Altimmune's pemvidutide preserved lean muscle mass while facilitating fat loss in obesity trials.

These advancements highlight a shift in pharmaceutical research, moving from mere weight reduction to comprehensive health enhancements. The industry's move towards holistic patient care could redefine standards in metabolic disease treatment.
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 5    | Content is fairly objective, with balanced reporting on various drug developments.    |
	| Social Impact | 4     | Content has sparked strong social discussion on new treatments, influencing public opinion.    |
	| Credibility    | 5    | Content is completely credible, with solid evidence from authoritative sources.    |
	| Potential    | 5    | Content has very high potential to trigger significant changes in metabolic disease treatment.    |
	| Practicality    | 4    | Content is highly practical, directly applicable to real health problems.    |
	| Entertainment Value    | 2    | Content is slightly monotonous but includes informative elements.    |
</TabItem>
</Tabs>

[Full article>>](https://www.cnbc.com/2024/06/26/healthy-returns-eli-lilly-drugmakers-show-off-weight-loss-drug-data.html)
